Alpa Laboratories Ltd. shows competitive metrics within the Pharmaceuticals & Drugs sector, particularly with a low PE ratio and solid profitability indicators, suggesting it is an undervalued player. However, it lags in growth compared to top performers in the sector, indicating potential for improvement.

• • Alpa Laboratories has a low PE ratio of 10.27, indicating undervaluation relative to peers.
• • It boasts a reasonable ROE of 11.71%, contributing to its profitability.
• • Revenue growth is modest at 3.41% YoY, suggesting less aggressive expansion than competitors.